Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone produced primarily by the placenta during pregnancy. It consists of two subunits, alpha and beta, with the beta subunit providing its biological specificity. HCG is synthesized by the syncytiotrophoblast cells of the placenta and is detectable in the blood and urine of pregnant women. It is also produced in small amounts by the pituitary gland in both men and women. Researchers have extensively studied HCG for its role in pregnancy, fertility treatments, and certain medical conditions. It is commonly used in assisted reproductive technologies to trigger ovulation and support early pregnancy. Additionally, HCG has been investigated for its potential effects on weight loss, although these claims are controversial and not widely supported by scientific evidence. The mechanism of action of HCG involves binding to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on target cells, primarily in the ovaries and testes. This interaction stimulates the production of sex steroids, such as progesterone and testosterone, which are crucial for maintaining pregnancy and supporting reproductive functions. Pharmacokinetically, HCG has a half-life of approximately 24 to 36 hours when administered intramuscularly or subcutaneously. It is relatively stable when stored properly, but its bioavailability can vary depending on the route of administration. Current research on HCG continues to explore its applications in reproductive medicine and oncology. It is approved for use in fertility treatments by regulatory agencies in many countries, but its use for other purposes, such as weight loss, is not supported by robust clinical evidence and is not approved by major health authorities.